|
Will A Global Subsidy Of New Antimalarials Delay The Emergence Of Resistance And Save Lives?
Ramanan Laxminarayan,
Mead Over and
David L. Smith
Artemisinin-based combination treatments (ACTs) are seen as an important tool in the global effort to roll back malaria. With parasite resistance to chloroquine increasing rapidly in many parts of the world, there is greater recognition of the need for a globally coordinated strategy to ensure that artemisinins are not used as monotherapy, which has the potential to cut short their useful therapeutic life. We find that even a partial subsidy could delay the emergence of resistance and that a delay in implementing a subsidy for ACTs could facilitate the emergence of resistance and lower the economic value of ACTs.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Laxminarayan and H. Gelband
A Global Subsidy: Key To Affordable Drugs For Malaria?
Health Aff.,
July 1, 2009;
28(4):
949 - 961.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bosman and K. N. Mendis
A Major Transition in Malaria Treatment: The Adoption and Deployment of Artemisinin-Based Combination Therapies
Am J Trop Med Hyg,
December 1, 2007;
77(6_Suppl):
193 - 197.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Gelband and A. Seiter
A Global Subsidy for Antimalarial Drugs
Am J Trop Med Hyg,
December 1, 2007;
77(6_Suppl):
219 - 221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
